NERATINIB (HKI-272), AN IRREVERSIBLE PAN ERBB RECEPTOR TYROSINE KINASE INHIBITOR: PHASE 2 RESULTS IN PATIENTS WITH ERBB2+ADVANCED BREAST CANCER

被引：0
|
作者：
Paridaens, R. [1 ]
Badwe, R. [2 ]
Sun, Y. [3 ]
Dirix, L. [4 ]
Cardoso, F. [5 ]
Powell, C. [6 ]
Zacharchuk, C. [7 ]
Burstein, H. J. [8 ]
机构：
[1] Univ Hosp Gasthuisberg Katholieke, Leuven, Belgium
[2] Tata Mem Hosp, Dept Surg Oncol, Mumbai 400012, Maharashtra, India
[3] Chinese Acad Med Sci, Beijing 100037, Peoples R China
[4] AZ St Augustinus, Oncol, Antwerp, Belgium
[5] Inst Jules Bordet, Med Oncol & Translat Res Unit, B-1000 Brussels, Belgium
[6] Wyeth Ayerst Res, Biostat, Cambridge, MA USA
[7] Wyeth Ayerst Res, Oncol, Cambridge, MA USA
[8] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [21] Safety and Efficacy of Neratinib (HKI-272) Plus Vinorelbine in the Treatment of Patients with ErbB2+Metastatic Breast Cancer Pretreated with Anti-HER2 Therapy
    Staroslawska, E.
    Dirix, L.
    Luu, T.
    Dieras, V.
    Manso, L.
    Xu, B.
    Yang, J.
    Abbas, R.
    Strahs, A.
    Van, M-L Vo
    Berkenblit, A.
    Agrapart, V.
    Powell, C.
    Awada, A.
    CANCER RESEARCH, 2010, 70
  • [22] Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
    Awada, A.
    Dirix, L.
    Manso Sanchez, L.
    Xu, B.
    Luu, T.
    Dieras, V.
    Hershman, D. L.
    Agrapart, V.
    Ananthakrishnan, R.
    Staroslawska, E.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 109 - 116
  • [23] Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
    Chow, L. W-C
    Xu, B.
    Gupta, S.
    Freyman, A.
    Zhao, Y.
    Abbas, R.
    Van, M-L Vo
    Bondarenko, I.
    BRITISH JOURNAL OF CANCER, 2013, 108 (10) : 1985 - 1993
  • [24] Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
    L W-C Chow
    B Xu
    S Gupta
    A Freyman
    Y Zhao
    R Abbas
    M-L Vo Van
    I Bondarenko
    British Journal of Cancer, 2013, 108 : 1985 - 1993
  • [25] Efficacy and Safety of Neratinib (HKI-272) in Combination with Paclitaxel in Her2+Metastatic Breast Cancer
    Chow, L.
    Gupta, S.
    Hershman, D. L.
    Epstein, R.
    Bondarenko, I.
    Van, M-L Vo
    Freyman, A.
    Zhao, Y.
    Abbas, R.
    Awada, A.
    CANCER RESEARCH, 2010, 70
  • [26] THE SAFETY OF NERATINIB (HKI-272) IN COMBINATION WITH CAPECITABINE IN PATIENTS WITH SOLID TUMORS: A PHASE 1/2 STUDY
    Saura, C.
    Martin, M.
    Moroose, R.
    Harb, W.
    Liem, K.
    Arena, F.
    Wade, M.
    Powell, C.
    Shapiro, M.
    Orfali, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 63 - 63
  • [27] Safety of Neratinib (HKI-272) in Combination with Capecitabine in Patients with Solid Tumors: A Phase 1/2 Study
    Saura, C.
    Martin, M.
    Moroose, R.
    Harb, W.
    Liem, K.
    Arena, F.
    Gressler, V
    Cortes, J.
    Wade, M.
    Powell, C.
    Shapiro, M.
    CANCER RESEARCH, 2009, 69 (24) : 801S - 802S
  • [28] Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations
    Piha-Paul, S. A.
    Tseng, C.
    Tran, H. T.
    Naing, A.
    Dumbrava, E. E.
    Karp, D. D.
    Rodon, J.
    Yap, T. A.
    Raghav, K. P.
    Damodaran, S.
    Le, X.
    Soliman, P. T.
    Lim, J.
    Meric-Bernstam, F.
    ESMO OPEN, 2025, 10 (02)
  • [29] Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
    Schwab, C. L.
    English, D. P.
    Black, J. D.
    Lopez, S.
    Bellone, S.
    Roque, D. M.
    Ratner, E. S.
    Silasi, D. A.
    Azodi, M.
    Rutherford, T. J.
    Schwartz, P. E.
    Santin, A.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 61 - 61
  • [30] Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
    Ma, Fei
    Li, Qiao
    Chen, Shanshan
    Zhu, Wenjie
    Fan, Ying
    Wang, Jiayu
    Luo, Yang
    Xing, Puyuan
    Lan, Bo
    Li, Meiying
    Yi, Zongbi
    Cai, Ruigang
    Yuan, Peng
    Zhang, Pin
    Li, Qing
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (27) : 3105 - +
12345